What Happened?
Washington, DC-based Regenxbio Appointed Mark Murphy as Senior Vice President, Finance
Date of management change: April 15, 2022
Washington, DC-based Regenxbio Appointed Mark Murphy as Senior Vice President, Finance
Regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. Regenxbio`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on Regenxbio`s NAV Technology Platform. Regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Mark Murphy is Senior Vice President, Finance at Regenxbio. Previously, Mark held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Holloway Sissy, Kamien Rich, Kropp Richard, Wilson Marcie, Slovina Dave, Colby Jim, Boutwell Danielle, Quezada Jeffrey, Ratcliffe Keff, Prickel Elaine, Dragomir Miruna
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.